Evidence map›Paper›PMID 39815050›Full record

ArticleLeukemia2025

Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis.

Axel Rüfer, Henning Nilius, Olivier Hermine, Marek Niedoszytko, Joanne N G Oude Elberink, Patrizia Bonadonna, Khalid Shoumariyeh, Theo Gulen, Karin Hartmann, Vito Sabato and 34 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors.

Axel RüferDepartment of Hematology, Luzerner Kantonsspital, University of Luzern, Luzern, Switzerland. axel.ruefer@luks.ch.ORCID http://orcid.org/0000-0003-2617-1724
Henning NiliusDepartment of Clinical Chemistry, University Hospital Bern, Inselspital, Bern, Switzerland.ORCID http://orcid.org/0000-0002-1323-3116
Olivier HermineHôpital Necker, Imagine Institute INSERM U1163, University of Sorbonne Paris Cité, Centre national de référence des mastocytoses, Paris, France.
Marek NiedoszytkoDepartment of Allergology, Medical University of Gdansk, Gdansk, Poland.
Joanne N G Oude ElberinkUniversity Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Patrizia BonadonnaAllergy Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
Khalid ShoumariyehDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Theo GulenDepartment of Respiratory Medicine and Allergy, Karolinska University Hospital, Huddinge, Stockholm; and Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.
Karin HartmannUniversitätsspital Basel, Basel, Switzerland.
Vito SabatoUniversiteit Antwerpen, Campus Drie Eiken, Antwerp, Belgium.
Irena Angelova-FischerKlinik für Dermatologie und Venerologie, Kepler Universitätsklinikum, Linz, Austria.
Daniel BaffoeDepartments of Hematology and Pharmacology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Deborah ChristenCenter for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany & Department of Haematology, Oncology, Haemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
Anna Belloni FortinaPediatric Dermatology, Internal Medicine, Azienda Ospedaliera, Università di Padova, Padova, Italy.
Christine BreynaertKU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group and MASTeL, UZ Leuven, Leuven, Belgium.
Knut BrockowKlinik und Poliklinik für Dermatologie und Allergologie am Biederstein; Technische Universität München, München, Germany.
Nikolas von BubnoffDepartment for Hematology and Oncology, Universitätsklinikum Schleswig-Holstein and University Cancer Center Schleswig-Holstein, Lübeck, Germany.ORCID http://orcid.org/0000-0001-9593-8947
Horia BumbeaDepartment of Hematology, Bone Marrow Transplant Unit, Carol Davila University of Medicine and Pharmacy, Emergency University Hospital, Bucharest, Romania.
Paul van DaeleDepartment of Internal Medicine, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Michael DoubekBrno University Hospital, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-1269-6282
Ingunn DybedalDepartments of Hematology and Pharmacology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Chiara ElenaPoliclinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy.
Christos FokolorosMastocytosis Center, "Attikon" University Hospital of Athens, Athens, Greece.
Aleksandra GórskaDepartment of Allergology, Medical University of Gdansk, Gdansk, Poland.
Marc HeizmannKantonsspital Aarau AG, Medizinische Universitätsklinik, Hämatologie, Aarau, Switzerland.
Madlen JentzschMedical Clinic I, Universitätsklinikum Leipzig AöR, Leipzig, Germany.ORCID http://orcid.org/0000-0002-2270-0804
Saskia KleinUniversity Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0001-8847-2704
Johannes LübkeDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.ORCID http://orcid.org/0000-0003-0767-1504
Mattias MattssonDepartment of Hematology, Uppsala University Hospital, and Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
André MulderUniversity Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Jens PanseCenter for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany & Department of Haematology, Oncology, Haemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.ORCID http://orcid.org/0000-0001-6316-3112
Tanja Daniela SchugUniversitätsklinik für Dermatologie und Venerologie, Medical University of Graz, Graz, Austria.
Mariarita SciumèS.C. Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Alex StefanKlinik für Innere Medizin 3 - Schwerpunkt Hämatologie und Onkologie, Kepler Universitätsklinikum, Linz, Austria.
Marlena SztormowskaDepartment of Allergology, Medical University of Gdansk, Gdansk, Poland.
Judit VárkonyiDepartment of Hematology, Semmelweis University, Budapest, Hungary.
Friederike WortmannDepartment for Hematology and Oncology, Universitätsklinikum Schleswig-Holstein and University Cancer Center Schleswig-Holstein, Lübeck, Germany.ORCID http://orcid.org/0000-0002-8684-1710
Akif Selim YavuzDivision of Hematology, Istanbul Medical School, University of Istanbul, Istanbul, Turkey.
Martina SperrLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Jason GotlibUniversity of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8253-6156
Andreas ReiterDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.ORCID http://orcid.org/0000-0002-7718-6507
Massimo TriggianiDivision of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.
Wolfgang R SperrLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Peter ValentLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-0456-5095

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Expression of CD2, CD25 and/or CD30 in extracutaneous mast cells (MC) is a minor diagnostic criterion for systemic mastocytosis (SM) in the classification of the World Health Organization and International Consensus Classification. So far, it remains unknown whether expression of these antigens on MC is of prognostic significance in SM. We performed a retrospective multi-center study of patients with SM using the data set of the registry of the European Competence Network on Mastocytosis, including 5034 patients with various MC disorders. The percentage of CD2

Indexed as

CD2 AntigensInterleukin-2 Receptor alpha SubunitKi-1 AntigenMast CellsMastocytosis, SystemicAdolescentAdultAgedAged, 80 and overEuropeFemaleHumansMaleMiddle AgedPrognosisRegistriesCD2 AntigensIL2RA protein, humanInterleukin-2 Receptor alpha SubunitKi-1 Antigen

Identifiers

PMID39815050
PMCPMC11879856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.